More positive data about the Bristol Myers Squibb experimental drug mavacamten was revealed at last weekend’s American College of Cardiology meeting and simultaneously published in The Lancet.
The data showed improvement in how patients felt taking the drug, as reported and quantified by the patients themselves. The clinical trial participants filled out a questionnaire called the KCCQ, or Kansas City Cardiomyopathy Questionnaire, 6 different times over the 38 weeks that the trial was ongoing.
Analysis of these responses showed that just over a third of patients who took mavacamten reported a substantial improvement in symptoms, though not all participants responded to the drug. And, it is important to note that the improvements seen by patients returned to baseline once mavacamten was discontinued.
Mavacamten, formerly known as MYK-461, was developed by the San Francisco based company MyoKardia and acquired by Bristol Myers Squibb late last year for $13.1 billion.
You can read more about these results in
American Journal of Managed Care
and here is an interview with Dr. Jay Edelberg of Bristol Myers Squibb about mavacamten.
Read more about history of mavacamten and other investigational drugs for HCM by searching the HCMBeat archives on the home page.
HCM Beat 
2 thoughts on “More Positive Data on Mavacamten Presented at ACC Meeting”